adalimumab + secukinumab + ixekizumab + guselkumab + janus kinase inhibitors + methotrexate

This is a combination regimen consisting of six distinct immunomodulatory and immunosuppressive agents, each with different mechanisms of action, primarily used in the management of autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. The components are: - **Adalimumab**: A monoclonal antibody targeting tumor necrosis factor alpha (TNFα), reducing inflammation. - **Secukinumab** and **Ixekizumab**: Monoclonal antibodies that inhibit interleukin-17A (IL-17A), blocking pro-inflammatory signaling. - **Guselkumab**: A monoclonal antibody targeting interleukin-23 (IL-23) p19 subunit, inhibiting downstream inflammatory pathways. - **Janus kinase inhibitors (JAK inhibitors)**: Small molecules that block Janus kinases involved in cytokine receptor signaling for multiple pro-inflammatory cytokines. - **Methotrexate**: An antimetabolite with anti-inflammatory effects via increased extracellular adenosine and inhibition of JAK1/JAK2 activity[1]. This combination would represent an extremely aggressive immunosuppressive approach not typically used in clinical practice due to overlapping mechanisms, high risk for adverse events including infection and malignancy, and lack of supporting evidence for combined use at this scale.